Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.94%
-0.21%
-1.07%
+0.75%
+0.48%
ABBV
AbbVie
$185.49
Chart
$185.58 (-0.05%)
$201.3 (-7.85%)
$201.3 (-7.85%)
$167.25 (+10.91%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.94%
-0.21%
-1.07%
+0.75%
+0.48%
ABBV
AbbVie
Current Price
$185.49
Login to view AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
Chart
$185.58 (-0.05%)
$201.3 (-7.85%)
$201.3 (-7.85%)
$167.25 (+10.91%)
ABBV Latest Analysis
AbbVies Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial. ) on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability safety and efficacy of atogepant (QULIPTA/AQUIPTA 60 mg once daily) compared to the highest tolerated dose of topiramate (50 75 or 100 mg/day) in adult patients with a history of four or more .The study met the primary endpoint of treatment discontinuation due to adverse events (AEs) demonstrating that atogepant a calcitonin
Today
AbbVie succeeds in late-stage migraine treatment trial.
Today
AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane . (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Wednesday positive topline results from its Phase 3 TEMPLE multicenter randomized double-blind head-to-head study evaluating the tolerability safety and efficacy of atogepant (QULIPTA/AQUIPTA 60 mg once dail
Today
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?. The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So is it worth buying the stock?
Tue Jun 17, 2025
AbbVies Venclexta Misses Goal in Myelodysplastic Syndromes Study. Venclexta fails to meet survival goals in ABBVs phase III MDS study marking another clinical setback for the cancer drug.
Tue Jun 17, 2025
Giant-Cell Arteritis Market Heats up with AbbVies RINVOQ Approval | DelveInsight. Giant-cell Arteritis Market Heats up with AbbVie'.s RINVOQ Approval |. DelveInsightThe FDA has approved AbbVie'.s RINVOQ (upadacitinib) for the treatment of giant cell arteritis making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ'.s approval has sparked competit
Thu Jun 12, 2025
FDA Expands AbbVies Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED). Editor'.s Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.The United States Food and Drug Administration (FDA) approved a label expansion for ) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis Glecaprevir one of the two DAAs in Mavyret was Discove
Wed Jun 11, 2025
How Is The Market Feeling About AbbVie?. ) short percent of float has fallen 20.35% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...
Wed Jun 11, 2025
AbbVie wins FDA nod for a label expansion of Enanta-partnered antiviral.
Wed Jun 11, 2025
FDA Expands AbbVies Mavyret Label To Include Pediatric Patients With Hepatitis C Infection. The United States Food and Drug Administration (FDA) approved a label expansion for ) Mavyret (glecaprevir/pibrentasvir) an oral pangenotypic .It is now approved for adults and pediatric patients three years and older with acute or chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.Glecaprevir one of the two DAAs in Mavyret was Discovered by ) and developed and comme
Wed Jun 11, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
